LCT, Otsuka Pharmaceutical deal

Living Cell said it has begun negotiations to grant Otsuka rights to develop and commercialize Living Cell's DiabeCell in Japan and other Asian countries, excluding China. DiabeCell, which comprises encapsulated porcine pancreatic islet cells, is in Phase II testing to treat Type I diabetes. Living Cell said the negotiations are expected to be completed within six months. ...